Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Herceptin Should Be Used With Caution In Pulmonary Compromised Patients

Executive Summary

Genentech is revising Herceptin labeling to add warnings about fatal hypersensitivity, infusion and pulmonary reactions in breast cancer patients being treated with the anti-HER2 oncologic.

You may also be interested in...



Herceptin Serious Infusion-Related AEs Hold At .25% Of Patients - Genentech

The reporting rate for serious infusion-related adverse events for Genentech's breast cancer agent Herceptin (trastuzumab) has not changed from the .25% of treated patients reported in May, the company indicated after issuing a "Dear Doctor" letter Oct. 6 notifying healthcare professionals of updates to warnings in labeling.

Herceptin Serious Infusion-Related AEs Hold At .25% Of Patients - Genentech

The reporting rate for serious infusion-related adverse events for Genentech's breast cancer agent Herceptin (trastuzumab) has not changed from the .25% of treated patients reported in May, the company indicated after issuing a "Dear Doctor" letter Oct. 6 notifying healthcare professionals of updates to warnings in labeling.

Genentech Herceptin

Label will be revised to stress precautions that the breast cancer therapy Herceptin (trastuzumab) be reconstituted with 20 mL of bacteriostatic water for injection as a diluent and that it be handled with caution during reconstitution. Genentech advised healthcare providers of the changes in a recent letter

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel